奥密克戎时期SARS-CoV-2感染后新发糖尿病:匹配队列研究
该研究利用关联登记数据构建基于人群的匹配队列,将2021年12月15日至2022年12月31日确诊COVID-19的≥16岁个体按年龄、性别和COVID-19疫苗近期接种情况与无COVID-19者匹配。在中位随访200天的5 736 501对匹配个体中,45 816例启动糖尿病治疗;COVID-19组后续启动糖尿病治疗的风险较无COVID-19组高14%(aHR 1.14;95%CI 1.12–1.17),但作者指出因潜在未测量混杂和检测偏倚,真实因果效应可能很小甚至为零。
要点
- 奥密克戎主导期SARS-CoV-2感染与后续启动糖尿病治疗风险轻度升高相关(aHR 1.14)。
- 接种不超过两剂COVID-19疫苗者风险高于近90天内接种加强针者。
- 阴性对照结局也出现类似关联,提示可能存在未测量混杂或检测偏倚。
核心结论
- 奥密克戎主导期SARS-CoV-2感染后启动糖尿病治疗的风险轻度升高,但真实因果效应可能很小甚至为零。
研究设计与样本
- 基于关联登记数据的基于人群匹配队列研究,纳入≥16岁个体,按年龄、性别和COVID-19疫苗近期接种情况匹配,使用病因特异性Cox模型并评估阴性对照结局。
主要发现
- 5 736 501对匹配个体中位随访200天,45 816例启动糖尿病治疗。
- COVID-19组较无COVID-19组启动糖尿病治疗的aHR为1.14(95%CI 1.12–1.17)。
- 接种不超过两剂疫苗者aHR为1.22(95%CI 1.18–1.25),近90天内接种加强针者aHR为1.08(95%CI 1.04–1.12)。
- COVID-19与阴性对照结局之间也观察到相似关联,但发生率模式不同。
临床怎么用
- 在奥密克戎流行期,对SARS-CoV-2感染者可关注糖尿病相关症状及治疗启动情况,但需认识到观察到的风险升高可能部分源于偏倚。
- 评估COVID-19后糖尿病风险时应考虑疫苗接种近期状态,近90天内接种加强针者风险估计较低。
局限性
- 存在潜在未测量混杂和检测偏倚,真实因果效应可能很小甚至为零。
- 阴性对照结局也出现类似关联,提示观察性关联可能受偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Earlier studies have suggested that SARS-CoV-2 infection increases the risk of subsequently developing diabetes. However, reports are more limited and inconsistent for infection with the Omicron variant and how COVID-19 vaccination may alter the risks. METHODS: A population-based, matched cohort study was conducted by using linked registry data. Individuals aged ≥16 years diagnosed with COVID-19 between 15 December 2021 and 31 December 2022 were matched to those without COVID-19 by age, sex, and COVID-19 vaccine recency. Cause-specific Cox models were used to estimate the association between COVID-19 and the initiation of diabetes treatment, adjusting for relevant demographic, healthcare-utilization, and health-related factors. Negative control outcomes were assessed. RESULTS: Among 5 736 501 matched pairs with and without COVID-19, followed for a median of 200 days, 45 816 initiated diabetes treatment. Compared with those without COVID-19, individuals with COVID-19 had a 14% higher risk of subsequently initiating diabetes treatment [adjusted hazard ratio (aHR) 1.14; 95% confidence interval (CI) 1.12; 1.17]. The risk was higher for those who had received up to two COVID-19 vaccine doses compared with those who had received a booster within the last 90 days (aHR 1.22; 95% CI 1.18, 1.25 vs aHR 1.08; 95% CI 1.04, 1.12). Similar associations were observed between COVID-19 and negative control outcomes while the incidence patterns differed. CONCLUSION: While we observed a small increased risk of diabetes following SARS-CoV-2 infection during the Omicron-dominant period, the true causal effect could be small or even null given the potential unmeasured confounding and detection bias. Future research on post-acute COVID-19 outcomes should consider including negative control outcomes to better detect potential biases.
引用
- Qian J, Stepien S, Cheng A, et al. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study. Int J Epidemiol. 2026. PMID: 41718663. doi:10.1093/ije/dyag009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。